Clinical study of high-dose chemotherapy with peripheral blood stem cell transplantation for poor-risk germ cell tumor by 岡村, 菊美 et al.
Title Poor-risk胚細胞腫瘍に対する末梢血幹細胞移植併用大量化学療法の検討
Author(s)岡村, 菊美; 弓場, 宏; 水谷, 一夫; 後藤, 百万; 小野, 佳成; 大島, 伸一; 直江, 知樹




Type Departmental Bulletin Paper
Textversionpublisher
Kyoto University








CLINICAL STUDY OF HIGH-DOSE CHEMOTHERAPY WITH 
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION 
FOR POOR-RISK GERM CELL TUMOR 
Kikuo OKAMURA， Hiroshi YUBAぅ KazuoMIZUTANI， 
Momokazu GOTOHラ Yoshinari ONO and Shinichi OHSHIMA 
From t的heDeψ戸αωr加 entqザfUrol臼ogy)NagりaUniversity School of Medicine 
Tomoki NAOE 
From the Department of lnfectious Diseasesフ NagりαUniversitySchool of Medicine 
793 
Between January 1997 and December 1998ラsixpatients with germ cel tumor were treated with 
high-dose CEC : carboplatin (1ラ500mg/m2)ぅetoposide(1ラ200mg/m2) and cyclophosphamide (100 mg/ 
kg)うfollowedby peripheral blood stem cel1 transplantation (PBSCT) at Nagoya University Hospital. 
Four patients received one cycle ofhigh-dose CEC and two received two cycles. The reasons why the 
high-dose CEC was administered included : 1)refractory to the induction chemotherapy (AFP/ s-HCG 
elevated during the induction chemotherapy or prolonged half-life of each marker) in three patientsぅ2)
relapse in two patientsラ and3) consolidation in one with unresectable mediastinal residual tumor. 
There were no treatment-related deaths and grade 1 hepatotoxicity occurred in one (17%) patient. 
The median duration (range)仕omPBSCT until a granulocyte count of 500/μL and a platelet count of 
50フ000/μLwas 8.5 (8-11) and 11 (9-16) daysラrespectively. Ofthe six patients studiedう5responded to 
the treatment; two achieved a complete response (CR) and three achieved a partial response (PR) 
One patient achieving a CR and two achieving a PR remained in complete remission after 23 to 24 
months offollow-upラwhilethe remaining patients with a CRラaPR and an incomplete response died of 
the disease. High-dose CEC could be administered without serious toxicity but the effectiveness of 
high-dose CEC for the poor-risk patients with germ cell tumor needs to be further investigated. 
(Acta Urol. Jpn. 45: 793-798ラ 1999)
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と方法
1997年 l月より 1998年12月までの 2年間に，名古屋
大学医学部前属病院泌尿器科にて PBSCT併用大量














認める IIIBが l例 (No.4)，肺， リンパ節以外の臓















































末梢血幹細胞採取 (PBSCharvest :以下 PBSCH
と略す)を試みた時期は，初自治療例で，
療法 lコース日が3例 2コース自が2例であった.
再発例では， PBSCHのために VIP療法を 1例に，
大量 Etoposide療法を l例に施行した (Table2). 1 
コースにつき 2日の PBSCHを行った.
治療開始日を day-8とし， Carboplatin 500 mg/m2 
とEtoposide400 mg/m2をday-8， -6， -4に投与し，
Cyclophosphamide 50 mg/kgを day-6，-4に投与し
た. day-Oに PBSCTを行った. 6例中 4例が単回の




cCR (clinical complete response)， 50%以上の腫痛
縮小を cPR(partial response)，それ以外のものを
IR (incomplete response) とした.残存腫蕩に対す
Peripheral blood stem cell harvest (PBSCH) Table 2. 
















Start of GCSF subcutaneous injection 
BEP (1 : dll) 
BEP (2: d14) 
VIP (3: d12) 
BEP (1: dll) 
BEP (2: d12) 
HD-VPI6 (1:出1)
BEP (1 : d14) 
G-CSF (μg) 
N artograstim (100) 
Filgrastim (150) 












day when starting GSCF). 
Toxicity of High聞doseCEC wi th PBSCT Table 3. 

























1 ( 17) 
6 (100) 
4 ( 67) 
3 ( 50) 
3 ( 50) 
1 ( 17) 
Non-hematologic toxicity 
Peak serum creatinin>2 mg/dL 
Elevated bilirubinラASTor ALP >2-5x normal range 
N ause and vomiting 
Fever beyond 380C 
Diarrhea 
N asal bleeding 
Arrythmia 
Days to plate1et>50う000/μL*
* : Number of days from peripheral blood stem cel transplantation. 


































。 50 100 150 200 250 Days 
Fig. 1. Clinical chart of the patient with resis-
tant tumor (No. 6). 
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30 120 Days 60 90 
Fig. 2. Clinical chart of the patient with absolute cispla-






た1， 4 ， 5 ， 9~11 ， 1十 17) 大量といっても無制限に薬剤を増
量できるわけではない.併用療法においては骨髄抑制
以外の副作用のため Carboplatinの最大耐容量(以
下 MTDと略す)は 2，100-2，250mg/m2， Etopo同
sideは 1，200-2，400mg/m2， Cyclophosphamide は




mg/m2， Etoposideが 1，200mg/m2， Cyclophospha-
mideが 100mg/kgといづれも最大耐容量(以下
MTDと略す)には達していない. しかし， Carbo-








かと推測している 14) 近年，大量化学療法を lコー
ス施行するより 2コース施行する方が有効注が高いの















再発症例， 2) IGCCC (以前は IUC)に基づく poor-






れている22) 本検討の 2例は初回治療で CRが，初j
797 
回再発時においても通常量救済化学療法により PR
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